Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: MYO5A

Gene summary for MYO5A

Gene summary.

Gene information	Species	Human
	Gene symbol	MYO5A
	Gene ID	4644
	Gene name	myosin VA
	Gene Alias	GS1
	Cytomap	15q21.2
	Gene Type	protein-coding
	GO ID	GO:0006810
	UniProtAcc	Q9UES4

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
4644	MYO5A	LZE4T	Human	Esophagus	ESCC	1.20e-11	4.39e-01	0.0811
4644	MYO5A	LZE7T	Human	Esophagus	ESCC	9.74e-03	3.00e-01	0.0667
4644	MYO5A	P2T-E	Human	Esophagus	ESCC	8.36e-10	6.83e-02	0.1177
4644	MYO5A	P4T-E	Human	Esophagus	ESCC	5.39e-13	1.71e-01	0.1323
4644	MYO5A	P5T-E	Human	Esophagus	ESCC	2.16e-14	1.14e-01	0.1327
4644	MYO5A	P8T-E	Human	Esophagus	ESCC	2.14e-07	4.80e-02	0.0889
4644	MYO5A	P9T-E	Human	Esophagus	ESCC	6.16e-06	1.44e-01	0.1131
4644	MYO5A	P10T-E	Human	Esophagus	ESCC	4.71e-10	2.24e-01	0.116
4644	MYO5A	P11T-E	Human	Esophagus	ESCC	2.14e-12	3.89e-01	0.1426
4644	MYO5A	P12T-E	Human	Esophagus	ESCC	2.03e-08	1.78e-01	0.1122
4644	MYO5A	P15T-E	Human	Esophagus	ESCC	3.28e-11	3.30e-01	0.1149
4644	MYO5A	P16T-E	Human	Esophagus	ESCC	7.69e-11	6.20e-02	0.1153
4644	MYO5A	P19T-E	Human	Esophagus	ESCC	2.62e-02	2.94e-01	0.1662
4644	MYO5A	P20T-E	Human	Esophagus	ESCC	5.10e-04	1.14e-01	0.1124
4644	MYO5A	P21T-E	Human	Esophagus	ESCC	1.53e-11	2.05e-01	0.1617
4644	MYO5A	P22T-E	Human	Esophagus	ESCC	9.93e-16	2.32e-01	0.1236
4644	MYO5A	P23T-E	Human	Esophagus	ESCC	3.32e-09	2.52e-01	0.108
4644	MYO5A	P24T-E	Human	Esophagus	ESCC	4.75e-07	1.44e-01	0.1287
4644	MYO5A	P26T-E	Human	Esophagus	ESCC	3.53e-18	3.61e-01	0.1276
4644	MYO5A	P27T-E	Human	Esophagus	ESCC	1.56e-07	7.52e-02	0.1055

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:005165022	Oral cavity	EOLP	establishment of vesicle localization	35/2218	161/18723	2.54e-04	2.47e-03	35
GO:005164822	Oral cavity	EOLP	vesicle localization	37/2218	177/18723	3.88e-04	3.48e-03	37
GO:00330592	Oral cavity	EOLP	cellular pigmentation	13/2218	53/18723	7.67e-03	3.66e-02	13
GO:0043473	Oral cavity	EOLP	pigmentation	20/2218	98/18723	1.02e-02	4.58e-02	20
GO:009951812	Oral cavity	EOLP	vesicle cytoskeletal trafficking	16/2218	73/18723	1.04e-02	4.65e-02	16
GO:000701534	Oral cavity	NEOLP	actin filament organization	94/2005	442/18723	4.49e-11	5.80e-09	94
GO:190165331	Oral cavity	NEOLP	cellular response to peptide	78/2005	359/18723	7.21e-10	5.54e-08	78
GO:003070531	Oral cavity	NEOLP	cytoskeleton-dependent intracellular transport	46/2005	195/18723	1.81e-07	6.18e-06	46
GO:007137531	Oral cavity	NEOLP	cellular response to peptide hormone stimulus	60/2005	290/18723	3.92e-07	1.19e-05	60
GO:004819331	Oral cavity	NEOLP	Golgi vesicle transport	60/2005	296/18723	8.09e-07	2.21e-05	60
GO:003286931	Oral cavity	NEOLP	cellular response to insulin stimulus	45/2005	203/18723	1.56e-06	3.86e-05	45
GO:004343431	Oral cavity	NEOLP	response to peptide hormone	76/2005	414/18723	1.79e-06	4.33e-05	76
GO:007265931	Oral cavity	NEOLP	protein localization to plasma membrane	56/2005	284/18723	4.51e-06	9.60e-05	56
GO:000689231	Oral cavity	NEOLP	post-Golgi vesicle-mediated transport	27/2005	104/18723	9.30e-06	1.79e-04	27
GO:199077831	Oral cavity	NEOLP	protein localization to cell periphery	62/2005	333/18723	9.84e-06	1.86e-04	62
GO:005165631	Oral cavity	NEOLP	establishment of organelle localization	69/2005	390/18723	1.89e-05	3.16e-04	69
GO:003286832	Oral cavity	NEOLP	response to insulin	50/2005	264/18723	4.35e-05	6.13e-04	50
GO:005165031	Oral cavity	NEOLP	establishment of vesicle localization	33/2005	161/18723	1.83e-04	1.99e-03	33
GO:005164831	Oral cavity	NEOLP	vesicle localization	34/2005	177/18723	5.23e-04	4.61e-03	34
GO:003004810	Oral cavity	NEOLP	actin filament-based movement	24/2005	127/18723	4.02e-03	2.29e-02	24

Page: 1 2 3 4 5 6 7 8

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa05130211	Esophagus	ESCC	Pathogenic Escherichia coli infection	142/4205	197/8465	8.21e-11	1.06e-09	5.42e-10	142
hsa05130310	Esophagus	ESCC	Pathogenic Escherichia coli infection	142/4205	197/8465	8.21e-11	1.06e-09	5.42e-10	142
hsa0513042	Liver	HCC	Pathogenic Escherichia coli infection	129/4020	197/8465	2.02e-07	2.50e-06	1.39e-06	129
hsa0513052	Liver	HCC	Pathogenic Escherichia coli infection	129/4020	197/8465	2.02e-07	2.50e-06	1.39e-06	129
hsa0513030	Oral cavity	OSCC	Pathogenic Escherichia coli infection	129/3704	197/8465	4.32e-10	5.17e-09	2.63e-09	129
hsa05130114	Oral cavity	OSCC	Pathogenic Escherichia coli infection	129/3704	197/8465	4.32e-10	5.17e-09	2.63e-09	129
hsa0513045	Oral cavity	EOLP	Pathogenic Escherichia coli infection	54/1218	197/8465	1.10e-06	9.96e-06	5.87e-06	54
hsa0513055	Oral cavity	EOLP	Pathogenic Escherichia coli infection	54/1218	197/8465	1.10e-06	9.96e-06	5.87e-06	54
hsa0513063	Oral cavity	NEOLP	Pathogenic Escherichia coli infection	55/1112	197/8465	2.04e-08	4.32e-07	2.72e-07	55
hsa048145	Oral cavity	NEOLP	Motor proteins	37/1112	193/8465	1.06e-02	3.54e-02	2.22e-02	37
hsa0513073	Oral cavity	NEOLP	Pathogenic Escherichia coli infection	55/1112	197/8465	2.04e-08	4.32e-07	2.72e-07	55
hsa0481412	Oral cavity	NEOLP	Motor proteins	37/1112	193/8465	1.06e-02	3.54e-02	2.22e-02	37

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

MYO5A

SNV

Missense_Mutation

novel

c.3088N>A

p.Glu1030Lys

p.E1030K

Q9Y4I1

protein_coding

tolerated(0.15)

benign(0.007)

TCGA-A2-A4S3-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

MYO5A

SNV

Missense_Mutation

c.3040N>C

p.Asp1014His

p.D1014H

Q9Y4I1

protein_coding

tolerated(0.07)

benign(0.01)

TCGA-A8-A06Q-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

MYO5A

SNV

Missense_Mutation

c.3578G>C

p.Arg1193Thr

p.R1193T

Q9Y4I1

protein_coding

tolerated(0.38)

benign(0)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYO5A

SNV

Missense_Mutation

rs751712752

c.5404C>T

p.Arg1802Cys

p.R1802C

Q9Y4I1

protein_coding

deleterious(0)

probably_damaging(0.931)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYO5A

SNV

Missense_Mutation

rs561485938

c.2438G>A

p.Arg813His

p.R813H

Q9Y4I1

protein_coding

deleterious(0)

possibly_damaging(0.815)

TCGA-BH-A1EN-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYO5A

SNV

Missense_Mutation

rs770697352

c.3361G>A

p.Glu1121Lys

p.E1121K

Q9Y4I1

protein_coding

tolerated(0.05)

benign(0.107)

TCGA-C8-A12Q-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

MYO5A

SNV

Missense_Mutation

novel

c.5122A>G

p.Lys1708Glu

p.K1708E

Q9Y4I1

protein_coding

deleterious(0)

probably_damaging(0.98)

TCGA-E2-A1B1-01

Breast

breast invasive carcinoma

Female

<65

I/II

Other, specify in notesbiphosphonate

zoledronic

MYO5A

insertion

Nonsense_Mutation

novel

c.3658_3659insGACATAACTTTAACTCCACAGACCTACGATAAGAATTT

p.Asn1220ArgfsTer11

p.N1220Rfs*11

Q9Y4I1

protein_coding

TCGA-A2-A0CP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

MYO5A

insertion

Frame_Shift_Ins

novel

c.5465_5466insG

p.His1823ThrfsTer57

p.H1823Tfs*57

Q9Y4I1

protein_coding

TCGA-A7-A26I-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

cytoxan

MYO5A

insertion

Frame_Shift_Ins

novel

c.5465_5466insG

p.His1823ThrfsTer57

p.H1823Tfs*57

Q9Y4I1

protein_coding

TCGA-AC-A3QQ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1